Weifang Ruze New Material Co., Ltd.

 

Your Aspiration is Our Commitment

Home
Products
About Us
Factory Tour
Quality Control
Contact Us
Request A Quote
Home ProductsNon Small Cell Lung Cancer Medications

NSCLC Drugs Afatinib 439081-18-2 Irreversible EGFR / HER2 Inhibitor With EFGR Agents 99% Assay

Ruze supply good service, thanks.

—— Gaurav

I'm Online Chat Now

NSCLC Drugs Afatinib 439081-18-2 Irreversible EGFR / HER2 Inhibitor With EFGR Agents 99% Assay

China NSCLC Drugs Afatinib 439081-18-2 Irreversible EGFR / HER2 Inhibitor With EFGR Agents 99% Assay supplier
NSCLC Drugs Afatinib 439081-18-2 Irreversible EGFR / HER2 Inhibitor With EFGR Agents 99% Assay supplier NSCLC Drugs Afatinib 439081-18-2 Irreversible EGFR / HER2 Inhibitor With EFGR Agents 99% Assay supplier

Large Image :  NSCLC Drugs Afatinib 439081-18-2 Irreversible EGFR / HER2 Inhibitor With EFGR Agents 99% Assay

Product Details:

Place of Origin: Weifang,China
Brand Name: RuzE
Model Number: TC-9067

Payment & Shipping Terms:

Minimum Order Quantity: Negotiable
Price: Negotiable
Packaging Details: 100g, 1kg Alumium Foil Bag
Delivery Time: 5-10work days
Payment Terms: L/C, Western Union, MoneyGram, T/T
Supply Ability: 25kg/Month
Contact Now
Detailed Product Description
Product Name: Afatinib (BIBW 2992)439081-18-2 CAS: 439081-18-2
MF: C24H25ClFN5O3 MW: 485.944
EINECS: 1308068-626-2 Mol File: 439081-18-2.mol

Weifang Ruze New Material Co.,LTD a China supplier of Afatinib (BIBW 2992) (CAS No.: 850140-72-6),CAS850140-72-6 offers for your requirements of RND, evaluation, pilots and commercial along with supportive technical package required for evaluation.

NSCLC Drugs Afatinib 439081-18-2 Irreversible EGFR / HER2 Inhibitor With EFGR Agents 99% Assay

 

Afatinib Irreversible EGFR/HER2 inhibitor CAS# 439081-18-2

 

[CAS No].850140-72-6

[Chemical Name]:Afatinib

[Molecular Formula]:C24H25ClFN5O3

[Formula Weight]:485.9384032

[Assay]:99%

[Appearance]:white Powder
[Stock]: less than 10kg

[Customer Synthesis] : Availabe

[Package]:100g, 500g, 1kg Foil bag/Bottle

 

Afatinib(439081-18-2) Chemical Properties,Uses,Production

 

General Description

 

Afatinib is a prescription medicine that can be taken orally for the treatment of non-small cell lung cancer (NSCLC) with atypical Epidermal Growth Factor Receptor (EFGR) agents. Afatinib is also prescribed for the treatment of NSCLC with the potential or radiating to other body tissues other than the lungs (metastatic cancer) as detected through an FDA approved examination. Afatinib is a 4-anilinoquinazoline tyrosine kinase suppressor that is available as a dimaleate salt (brand name: Giltrif). The drug is the first FDA-endorsed oncology product by Boehringer Ingelheim.

 

Indication

 

The drug is a kinase agonist that is indicated as monotherapy for EFGR and tyrosine kinase suppressor-naive adult patients whose NSCLC is metastatic or locally advanced and the tumours are resistant to EGFR mutations as approved by an FDA-endorsed examination. In addition, the adult patients should indicate signs of squamous histology progress at the time of platinum-based chemotherapy or after the sessions.


Afatinib (BIBW 2992) Chemical Properties


density 1.380
CAS DataBase Reference 439081-18-2

Safety Information


HS Code 29349990

Afatinib (BIBW 2992) Usage And Synthesis


 

Pharmacological effects Afatinib (BIBW 2992) is the second-generation potent and irreversible dual inhibitor of the epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) tyrosine kinase, developed by Boehringer Ingelheim, Germany. It is capable of irreversibly inhibiting the activity of the tyrosine kinase by undergoing the Michael reaction with the thiol group of cysteine at position 797 of the EGFR. On July 12, 2013, it became a new drug for anti-small cell lung cancer approved by the US FDA under the trade name of Gilotrif. This drug is a tablet. It is used for the treatment of the patients diagnosed with metastatic non-small cell lung cancer (NSCLC) with the loss of the 19th exon or L858R mutation in the 21th exon of the tumor epidermal growth factor receptor (EGFR) confirmed using the kit approved by FDA. The drug is also effective in the treatment of HER2-positive patients with advanced breast cancer.
Boehringer Ingelheim Pharmaceuticals has applied for the protection of this compound by applying patents JP2004516283 US2010010023 WO2002050043 and so on.
Lung cancer is the world's top tumor killer with the incidence in male being higher than that in women. The number of annually new diagnosed lung cancer patients can reach 1.6 million. However, lung cancer is not just a disease. Studies have shown that lung cancer contains many different types with different types of lung cancer needs to be given specific treatment. A specific subtype of lung cancer can be determined by EGFR (ErbB receptor family members) mutation detection. These patients are also those who can benefit from the most during the treatment with Afatinib in clinical trials.

 

 

 

NSCLC Drugs Afatinib 439081-18-2 Irreversible EGFR / HER2 Inhibitor With EFGR Agents 99% AssayNSCLC Drugs Afatinib 439081-18-2 Irreversible EGFR / HER2 Inhibitor With EFGR Agents 99% Assay

NSCLC Drugs Afatinib 439081-18-2 Irreversible EGFR / HER2 Inhibitor With EFGR Agents 99% AssayNSCLC Drugs Afatinib 439081-18-2 Irreversible EGFR / HER2 Inhibitor With EFGR Agents 99% AssayNSCLC Drugs Afatinib 439081-18-2 Irreversible EGFR / HER2 Inhibitor With EFGR Agents 99% Assay

 

NSCLC Drugs Afatinib 439081-18-2 Irreversible EGFR / HER2 Inhibitor With EFGR Agents 99% Assay

Weifang Ruze New Material Co.,LTD supply free sample and datebase on Afatinib (BIBW 2992) (CAS No.: 850140-72-6), if you want futher information about Afatinib (BIBW 2992) (CAS No.: 850140-72-6), please feel free to contract us.

Contact Details
Weifang Ruze New Material Co., Ltd.

Contact Person: Ruze02

Send your inquiry directly to us (0 / 3000)